Academic Drug Discovery Support by TRxA – Hosted by UConn TCS

The Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) is a global drug discovery and development program focused on supporting academic scientists in defining and funding optimal strategies for advancing new, cutting-edge therapeutics from the lab to patients. TRxA’s nonprofit accelerator model accomplishes this by:

• Providing resources and hands-on guidance, with TRxA staff working closely with academic researchers to develop a comprehensive data package for potential drug candidates.

• Providing tactical and strategic drug discovery and development guidance, bringing diverse expertise to pivotal early-stage study design and implementation.

• Leveraging TRxA’s outsourcing model to facilitate involvement of contract research organizations (CROs) as necessary to perform critical experiments that cannot be conducted in the academic setting (e.g., key toxicology and other specialized studies). CROs may also be engaged for third-party validation of academic studies to develop the type of comprehensive and validated data package pharmaceutical companies require when making decisions about licensing opportunities.

TRxA will have a call for proposals in early 2023 and eligibility criteria will be reviewed during this presentation

Speaker: Maaike Everts

Maaike Everts, PhD, a pharmaceutical scientist with broad experience in drug delivery, discovery and development, is Executive Director of the Critical Path Institute’s Translational Therapeutics Accelerator. Prior to C-Path, she had a leadership role with Parenteral Drug Delivery Solutions at Evonik Health Care, responsible for shaping the drug delivery technology and manufacturing platforms offered by the organization as well as positioning them in the marketplace. Before joining Evonik, Maaike was a full professor at the University of Alabama at Birmingham (UAB), in the School of Medicine, where she structured and lead the Alabama Drug Discovery Alliance, a venture between UAB and Southern Research, and the Antiviral Drug Discovery and Development Consortium, funded by the National Institutes of Health. She had been at UAB since 2002, initially as a postdoctoral scholar in its Gene Therapy Center, where she combined adenoviral based vectors with nanotechnology. She received her Ph.D. in Pharmacokinetics and Drug Delivery from the University of Groningen in the Netherlands.